Publicaciones en las que colabora con Jordi Bruix Tudó (33)

2022

  1. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  4. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  5. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

    Liver Transplantation, Vol. 27, Núm. 12, pp. 1767-1778

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

    American Journal of Transplantation, Vol. 19, Núm. 11, pp. 3176-3184

2016

  1. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 719-726

2010

  1. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma

    European Journal of Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 1239-1244

  2. Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros

    Medicina Clinica, Vol. 134, Núm. 13, pp. 569-576

2009

  1. Diagnóstico y tratamiento del carcinoma hepatocelular

    Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287

  2. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?

    Cancer, Vol. 115, Núm. 3, pp. 616-623

2008

  1. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

    Hepatology, Vol. 47, Núm. 1, pp. 97-104

  2. Malignant Tumours

    Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition (Blackwell Publishing Ltd), pp. 1437-1463

2007

  1. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics

    Journal of Hepatology, Vol. 46, Núm. 3, pp. 474-481

  2. Hepatoma

    Medical Care of the Liver Transplant Patient: Third Edition (Blackwell Publishing Ltd), pp. 119-138

  3. Liver transplantation in hepatocellular carcinoma. Validity of the Milan criteria

    Gastroenterologia y Hepatologia

  4. Reply: Chemoembolization with drug eluting beads in HCC>

    Journal of Hepatology

2006

  1. Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure

    Liver Transplantation